A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
IGF2BP3 Associates with Proliferative Phenotype and Prognostic Features in B-Cell Acute Lymphoblastic Leukemia (2021)


Mäkinen, A., Nikkilä, A., Haapaniemi, T., Oksa, L., Mehtonen, J., Vänskä, M., Heinäniemi, M., Paavonen, T., & Lohi, O. (2021). IGF2BP3 Associates with Proliferative Phenotype and Prognostic Features in B-Cell Acute Lymphoblastic Leukemia. Cancers, 13(7), Article 1505. https://doi.org/10.3390/cancers13071505


JYU-tekijät tai -toimittajat


Julkaisun tiedot

Julkaisun kaikki tekijät tai toimittajat: Mäkinen, Artturi; Nikkilä, Atte; Haapaniemi, Teppo; Oksa, Laura; Mehtonen, Juha; Vänskä, Matti; Heinäniemi, Merja; Paavonen, Timo; Lohi, Olli

Lehti tai sarja: Cancers

eISSN: 2072-6694

Julkaisuvuosi: 2021

Volyymi: 13

Lehden numero: 7

Artikkelinumero: 1505

Kustantaja: MDPI

Julkaisumaa: Sveitsi

Julkaisun kieli: englanti

DOI: https://doi.org/10.3390/cancers13071505

Linkki tutkimusaineistoon: https://portal.gdc.cancer.gov/projects

Julkaisun avoin saatavuus: Avoimesti saatavilla

Julkaisukanavan avoin saatavuus: Kokonaan avoin julkaisukanava

Julkaisu on rinnakkaistallennettu (JYX): https://jyx.jyu.fi/handle/123456789/77137


Tiivistelmä

The oncofetal protein insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) belongs to a family of RNA-binding proteins involved in localization, stability, and translational regulation of target RNAs. IGF2BP3 is used as a diagnostic and prognostic marker in several malignancies. Although the prognosis of pediatric B-cell acute lymphoblastic leukemia (B-ALL) has improved, a subgroup of patients exhibits high-risk features and suffer from disease recurrence. We sought to identify additional biomarkers to improve diagnostics, and we assessed expression of IGF2BP3 in a population-based pediatric cohort of B-ALL using a tissue microarray platform. The majority of pediatric B-ALL cases were positive for IGF2BP3 immunohistochemistry and were associated with an increased proliferative phenotype and activated STAT5 signaling pathway. Two large gene expression data sets were probed for the expression of IGF2BP3—the highest levels were seen among the B-cell lymphomas of a germinal center origin and well-established (KMT2A-rearranged and ETV6-RUNX1) and novel subtypes of B-ALL (e.g., NUTM1 and ETV6-RUNX1-like). A high mRNA for IGF2BP3 was associated with a proliferative “metagene” signature and a high expression of CDK6 in B-ALL. A low expression portended inferior survival in a high-risk cohort of pediatric B-ALL. Overall, our results show that IGF2BP3 shows subtype-specificity in expression and provides prognostic utility in high-risk B-ALL.


YSO-asiasanat: syöpätaudit; leukemia; akuutti lymfaattinen leukemia; ennusteet; biomarkkerit; proteiinit; lähetti-RNA

Vapaat asiasanat: insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3); mRNA; pediatric B-cell acute lymphoblastic leukemia; prognosis; proliferation; protein


Liittyvät organisaatiot


OKM-raportointi: Kyllä

Raportointivuosi: 2021

JUFO-taso: 1


Viimeisin päivitys 2022-20-09 klo 15:22